GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sage Therapeutics Inc (FRA:SG7) » Definitions » Cyclically Adjusted PB Ratio

Sage Therapeutics (FRA:SG7) Cyclically Adjusted PB Ratio : 0.58 (As of Jun. 05, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sage Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-06-05), Sage Therapeutics's current share price is €10.175. Sage Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €17.61. Sage Therapeutics's Cyclically Adjusted PB Ratio for today is 0.58.

The historical rank and industry rank for Sage Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:SG7' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.58   Med: 1.92   Max: 3.29
Current: 0.58

During the past years, Sage Therapeutics's highest Cyclically Adjusted PB Ratio was 3.29. The lowest was 0.58. And the median was 1.92.

FRA:SG7's Cyclically Adjusted PB Ratio is ranked better than
73.03% of 660 companies
in the Biotechnology industry
Industry Median: 1.745 vs FRA:SG7: 0.58

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Sage Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was €10.790. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €17.61 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Sage Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Sage Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sage Therapeutics Cyclically Adjusted PB Ratio Chart

Sage Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 2.15 1.16

Sage Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.32 2.58 1.13 1.16 0.98

Competitive Comparison of Sage Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Sage Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sage Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sage Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Sage Therapeutics's Cyclically Adjusted PB Ratio falls into.



Sage Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Sage Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=10.175/17.61
=0.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sage Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Sage Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=10.79/131.7762*131.7762
=10.790

Current CPI (Mar. 2024) = 131.7762.

Sage Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 -1.321 100.560 -1.731
201409 4.031 100.428 5.289
201412 3.858 99.070 5.132
201503 3.830 99.621 5.066
201506 6.768 100.684 8.858
201509 6.131 100.392 8.048
201512 5.532 99.792 7.305
201603 8.058 100.470 10.569
201606 7.137 101.688 9.249
201609 9.919 101.861 12.832
201612 9.386 101.863 12.142
201703 7.981 102.862 10.224
201706 6.191 103.349 7.894
201709 4.473 104.136 5.660
201712 9.565 104.011 12.118
201803 18.491 105.290 23.143
201806 19.796 106.317 24.536
201809 18.090 106.507 22.382
201812 16.178 105.998 20.112
201903 22.882 107.251 28.115
201906 20.683 108.070 25.220
201909 18.944 108.329 23.044
201912 16.389 108.420 19.920
202003 14.803 108.902 17.912
202006 12.651 108.767 15.327
202009 10.732 109.815 12.878
202012 29.215 109.897 35.031
202103 28.811 111.754 33.973
202106 27.250 114.631 31.326
202109 26.521 115.734 30.197
202112 25.963 117.630 29.085
202203 24.881 121.301 27.030
202206 23.961 125.017 25.257
202209 23.430 125.227 24.655
202212 19.870 125.222 20.910
202303 17.709 127.348 18.325
202306 15.195 128.729 15.555
202309 12.760 129.860 12.948
202312 12.211 129.419 12.433
202403 10.790 131.776 10.790

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sage Therapeutics  (FRA:SG7) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Sage Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Sage Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sage Therapeutics (FRA:SG7) Business Description

Traded in Other Exchanges
Address
215 First Street, Cambridge, MA, USA, 02142
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABAA receptors. The NMDA-type receptors of the glutamate receptor system are a excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders.

Sage Therapeutics (FRA:SG7) Headlines

No Headlines